Breakthrough advances in oncology have produced a multitude of new treatment options, often with substantial clinical gains attached to significantly higher pricing. This rapidly evolving treatment landscape has ushered in attempts to quantify and compare the incremental value of new products, such as the American Society for Clinical Oncology (ASCO) Conceptual Framework to Assess the Value of Cancer Treatment Options. Manufacturers of oncology drugs must be prepared to present new and existing oncology products within the context of these frameworks, ensuring that the value of products is appropriately and fully characterized.
Join our featured speakers, Douglas Neely and Lisa Bloudek, for a complimentary webinar focusing on how these frameworks are currently perceived through sharing of comprehensive survey data from oncologists and payers. Additionally, the speakers will share strategies on how these frameworks can be leveraged by manufacturers to demonstrate product value, with a focus on the ASCO framework. During this webinar, participants will:
- Gain insights from oncologists and payers on the impact of value frameworks
- Understand how oncologists and payers interpret the frameworks, including strengths and areas for improvement
- Learn how oncology products will measure up under these frameworks, with implications for data generation in clinical trials and beyond
Doug Neely, CMPE, MHA, Senior Director, Xcenda
Doug Neely, CMPE, MHA, is a Senior Director and leads Xcenda’s Oncology Insights team. In this role, Doug and the Oncology Insights team support the development and implementation of brand strategies utilizing multiple market research tools and Xcenda’s proprietary network of advisors, the Global Provider Insights Network.
Mr. Neely brings 20 years experience of experience in healthcare, with 10 years spent on the provider side of the industry. He combines his firsthand experience working inside physician practices and hospitals with his knowledge of product commercialization to help clients develop effective brand and access strategies. He is an experience presenter (including the ACCC Annual Meeting and MGMA/AOHA) and has authored publications on reimbursement and access topics both in general and specifically related to oncology products.
Lisa Bloudek, PharmD, MS, Assistant Director, Xcenda
Lisa Bloudek, PharmD, MS, is an Assistant Director with the Economic Modeling team in Global Health Economics and Outcomes Research (GHEOR) Scientific Consulting at Xcenda. In this role, she is directly involved in observational research studies, systematic reviews, economic models, global value dossiers, and scientific publications. Dr. Bloudek has experience in the design and development of global economic models and also has expertise in patient-reported outcomes, clinical trials, systematic literature reviews and meta-analysis, Academy of Managed Care Pharmacy (AMCP) dossiers, and global value dossiers. She brings particular experience in the field of neurology and headache and has co-authored several manuscripts published in top-tier neurology and GHEOR journals such as the Journal of Alzheimer’s Disease, Journal of Headache and Pain, Headache, and Quality of Life Research.
Before joining Xcenda, Dr. Bloudek was a manager at a specialty Pharmaceutical company where she developed and oversaw the creation of economic models and GHEOR deliverables to aid global market access and reimbursement. She worked closely with key opinion leaders in the field of neurology to accomplish this research in collaboration with the most influential and respected thought leaders in the field.
Dr. Bloudek received her Doctor of Pharmacy and Master of Science degrees from the University of Washington Pharmaceutical Research and Policy Program in the School of Pharmacy. She also holds a Bachelor of Science degree from the University of Washington.Message Presenter
Who Should Attend?
Individuals interested in market access for specialty and biotechnology products in oncology, including professionals in:
- Provider, Payer, Patient Marketing
- Medical Affairs
- Market Access
- Managed Markets
- Reimbursement Strategy
Xcenda is a strategic consulting firm with 20 years of experience applying real-world expertise in health economics and outcomes research, reimbursement, health policy, market research, and market access strategy. We support global Pharmaceutical companies as well as emerging pre-commercialization phase firms with challenges such as developing an evidence package to optimize access in key global markets, predicting product performance, and identifying reimbursement strategies and programs to maximize patient access. From development through market maturity, Xcenda helps manufacturers identify, demonstrate, and deliver their brand’s value proposition to key healthcare stakeholders.
Xcenda is backed by an even wider breadth of healthcare knowledge and partnerships through AmerisourceBergen Corporation (NYSE: ABC), one of the world’s largest Pharmaceutical services companies. Xcenda’s strategic consulting services support the design of patient support services and specialty distribution programs to improve product access and adherence at every stage of its life cycle.